1. |
Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med, 2021, 47(11): 1181-1247.
|
2. |
Ma S, Evans RG, Iguchi N, et al. Sepsis-induced acute kidney injury: a disease of the microcirculation. Microcirculation, 2019, 26(2): e12483.
|
3. |
Poston JT, Koyner JL. Sepsis associated acute kidney injury. BMJ, 2019, 364: k4891.
|
4. |
冯长福, 周森, 邢柏. 可溶性 CD73 联合 SOFA 评分对脓毒症相关急性肾损伤患者 28 d 死亡风险的预测价值. 中国急救医学, 2022, 42(1): 13-18.
|
5. |
覃英镨, 刘焕皓. 枸橼酸抗凝剂用于血液净化的临床研究进展. 药物评价研究, 2018, 41(5): 929-933.
|
6. |
Legrand M, Tolwani A. Anticoagulation strategies in continuous renal replacement therapy. Semin Dial, 2021, 34(6): 416-422.
|
7. |
Pschowski R, Briegel S, Von Haehling S, et al. Effects of dialysis modality on blood loss, bleeding complications and transfusion requirements in critically ill patients with dialysis-dependent acute renal failure. Anaesth Intensive Care, 2015, 43(6): 764-770.
|
8. |
北村伸哉, 张凌. 甲磺酸萘莫司他在连续性肾脏替代治疗中的抗凝应用. 华西医学, 2018, 33(7): 801-805.
|
9. |
Doi K, Nishida O, Shigematsu T, et al. The Japanese clinical practice guideline for acute kidney injury 2016. Clin Exp Nephrol, 2018, 22(5): 985-1045.
|
10. |
Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med, 2021, 49(11): e1063-e1143.
|
11. |
Kidney Disease:Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl, 2012, 2(1): 1-138.
|
12. |
Karkar A, Ronco C. Prescription of CRRT: a pathway to optimize therapy. Ann Intensive Care, 2020, 10(1): 32.
|
13. |
Vlaar APJ, Dionne JC, de Bruin S, et al. Transfusion strategies in bleeding critically ill adults: a clinical practice guideline from the European Society of Intensive Care Medicine. Intensive Care Med, 2021, 47(12): 1368-1392.
|
14. |
Zarbock A, Küllmar M, Kindgen-Milles D, et al. Effect of regional citrate anticoagulation vs systemic heparin anticoagulation during continuous kidney replacement therapy on dialysis filter life span and mortality among critically ill patients with acute kidney injury: a randomized clinical trial. JAMA, 2020, 324(16): 1629-1639.
|
15. |
Thompson A, Li F, Gross AK. Considerations for medication management and anticoagulation during continuous renal replacement therapy. AACN Adv Crit Care, 2017, 28(1): 51-63.
|
16. |
Annich GM, Zaulan O, Neufeld M, et al. Thromboprophylaxis in extracorporeal circuits: current pharmacological strategies and future directions. Am J Cardiovasc Drugs, 2017, 17(6): 425-439.
|
17. |
Pellizzari L, Facchinetti R, Corrà L, et al. Can we reliably predict the level of anticoagulation after enoxaparin injection in elderly patients with renal failure?. Aging Clin Exp Res, 2018, 30(6): 605-608.
|
18. |
Lin T, Song L, Huang R, et al. Modified regional citrate anticoagulation is optimal for hemodialysis in patients at high risk of bleeding: a prospective randomized study of three anticoagulation strategies. BMC Nephrol, 2019, 20(1): 472.
|
19. |
Wen M, Küchle C, Steubl D, et al. A novel citrate-based protocol versus heparin anticoagulation for sustained low-efficiency dialysis in the ICU: safety, efficacy, and cost. BMC Nephrol, 2018, 19(1): 79.
|
20. |
Bianchi NA, Altarelli M, Eckert P, et al. Complications of regional citrate anticoagulation for continuous renal replacement therapy: an observational study. Blood Purif, 2020, 49(5): 567-575.
|
21. |
Ng CJH, Poh CB, Koduri S, et al. Regional citrate anti-coagulation dose titration: impact on dose of continuous renal replacement therapy. Clin Exp Nephrol, 2021, 25(9): 963-969.
|
22. |
杨晓波, 王金柱, 刘明晨, 等. 枸橼酸钠在脓毒症伴高危出血因素患者行连续性肾脏替代治疗中的应用效果分析. 护理与康复, 2018, 17(9): 10-14.
|
23. |
Li L, Bai M, Yu Y, et al. Regional citrate anticoagulation vs no-anticoagulation for CRRT in hyperlactatemia patients with increased bleeding risk: a retrospective cohort study. Semin Dial, 2020: 8.
|
24. |
Choi JY, Kang YJ, Jang HM, et al. Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk: a randomized clinical trial. Medicine (Baltimore), 2015, 94(52): e2392.
|
25. |
Makino S, Egi M, Kita H, et al. Comparison of nafamostat mesilate and unfractionated heparin as anticoagulants during continuous renal replacement therapy. Int J Artif Organs, 2016, 39(1): 16-21.
|